GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031. The drugmaker ...
PepsiCo reports stronger results as snack demand begins to recover, driven by affordability efforts, though its beverage segment continues to lag. Chili's launches six Big Crispy chicken sandwiches in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results